NIPH Clinical Trials Search

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Basic Information

Recruitment status	Pending
Health condition(s) or Problem(s) studied	Overweight Obesity
Date of first enrollment	23/03/2026
Target sample size	1035
Countries of recruitment	United States,Japan,Argentina,Japan,China,Japan,Czechia,Japan,Germany,Japan,India,Japan,Mexico,Japan,Poland,Japan,Puerto Rico,Japan,Slovakia,Japan,South Korea,Japan,Spain,Japan,Taiwan,Japan
Study type	Interventional
Intervention(s)	DRUG: Eloralintide(Other Name: LY3841136) Administered SC DRUG: Placebo Administered SC (Study Arms) Experimental: Eloralintide Dose 1 Participants will receive eloralintide subcutaneously (SC) Interventions: Drug: Eloralintide Experimental: Eloralintide Dose 2 Participants will receive eloralintide SC Interventions: Drug: Eloralintide Experimental: Eloralintide Dose 3 Participants will receive eloralintide SC Interventions: Drug: Eloralintide Experimental: Eloralintide Dose 4 Participants will receive eloralintide SC Interventions: Drug: Eloralintide Placebo Comparator: Placebo Participants will receive placebo SC Interventions: Drug: Placebo

Outcome(s)

Primary Outcome	Percent Change from Baseline in Body Weight [ Time Frame: Baseline, Week 64
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	- Have type 2 diabetes - Are on stable treatment for type 2 diabetes for at least 90 days prior to screening - Have a BMI >= 27 kg/m2 - Have a stable body weight (<5% body weight change) for 90 days prior to screening
Exclude criteria	- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening) - Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) - Have type 1 diabetes - Have taken any of the following antihyperglycemic medications within 90 days before screening: * amylin analogs * glucagon-like peptide-1 (GLP-1) receptor agonists * glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or * insulin - Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure - Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure - Have taken medications or alternative remedies intended for weight loss within 90 days of screening